Impact on obesity-related illnesses and quality of life following intragastric balloon.

Background: The impact of intragastric balloon (IGB) on obesity-related illnesses and quality of life (QOL) has not been previously investigated.

Method: One hundred and nineteen consecutive obese patients (86 females; mean age 37.8; mean body weight (BW) 103.

[Effectiveness and safety of intragastric balloon for treatment of morbid obesity].

Objective: To evaluate the effectiveness and safety of intragastric balloon (IGB) for the treatment of obese Chinese.

Methods: IGB was placed into the stomachs of 48 Chinese patients in Hong Kong, 13 males and 35 females; aged 39 +/- 9 (18 - 65), with the mean baseline body weight (BW) of 106 +/- 26 kg and mean body mass index (BMI) of (40 +/- 9) kg/m(2), 34 (70.8%) with coexistent obesity-related morbidities, who failed to respond to other weight reducing treatment, via routine gastroscopy under intravenous conscious sedation.

Intragastric balloon in ethnic obese Chinese: initial experience.

Background: We evaluated the effectiveness and safety of intragastric balloon (IGB) for the treatment of obesity in ethnic Chinese in Hong Kong.

Methods: 15 Chinese patients (10 females; median age 40 years (range 21-58)) completed IGB treatment over a 10-month period since November 2004. Median baseline body weight (BW) and BMI were 100.